Lipoatrophy after use of long acting insulin glargine analogue in a 32-year-old patient with type 1 diabetes;Lipoatrofia po zastosowaniu długo działaja̧cego analogu insuliny glarginy u 32-letniej pacjentki z cukrzyca̧ typu 1

Pediatric Endocrinology, Diabetes and Metabolism

Volumn 14, Issue 1, 2008, Pages 61-63

  Dziura, Maria ^a,c   Wa̧sikowa, Renata ^b  

^a Oddzia Diabetologiczny Miedziowego Centrum Zdrowia   (Poland)

^b Katedra I Klinika Endokrynologii Wieku Rozwojowego AM we Wroc awiu

^c Department of Cardiology   (Poland)

Author keywords

Insulin glargine; Lipoatrophy; Type 1 diabetes

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN; LONG ACTING DRUG;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIABETES CONTROL; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HASHIMOTO DISEASE; HUMAN; HYPERGLYCEMIA; HYPOTHYROIDISM; INSULIN DEPENDENT DIABETES MELLITUS; LIPOATROPHY; MEDICAL EXAMINATION; PATIENT ASSESSMENT; PATIENT REFERRAL; PROTEIN BLOOD LEVEL; SYMPTOM; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84904848263     PISSN: 1234625X     EISSN: 20838441     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Rosefeld I.: Insulin: discovery and controversy. Clin. Chem., 2002, 48, 2270-2288.
2. Vajo Z., Fawcett J., Duckworth W.C.: Recombinant DNA technology at the treatment of diabetes: insulin analogs. Endocr. Rev., 2001, 22, 706-717.
3. Jones R.: Insulin glargina (Aventis Pharma). Drugs, 2000, 3, 1081-1087.
4. Buse O.: Insulin glargine (HOE 901): first responsibilities: understanding the data and ensuring safety. Diabetes Care, 2000, 23, 576-578.
5. Oiknine R., Bembaum M., Mooradian AD.: A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs, 2005, 65, 325-340.
6. Aschwell S.G., Home P.D.: Insulin glargina: the first clinically useful extended-action insulin analogue. Exp. Opin. Pharmacother., 2001, 2, 1891-1902.
7. Wang F., Carabinio J.M., Vergara C.M.: Insulin glargina systemic review of long-acting insulin analogue. Clin. Ther., 2003, 6, 1541-1547.
8. Hervig J., Scholl-Schilling G., Bohles H.: Glycaemic control and hypoglycaemia in children, adolescents and young adults witch unstable type 1 diabetes mellitus treated glargine or intermediate insulin. Journal Pediatr. Endocrinol. Metab., 2007, 20, 517-527.
9. Garcia-Garcia E., Aquilera P. Galera. P. i wsp.: Long term use of continuous insulin infusion compared with multiple daily injections of glargina in pediatric patiens. J. Pediatr. Endocrinol. Metab., 2007, 20, 37-40.
10. Chakkawar P.N., Manjrekar N.A.: Insulin glargine: a long acting insulin analog. J. Postgrad. Med., 2005, 51, 68-71.
11. Durand Gonzales K.N., Guillausseau N., Pecquet C.: Glargine insulin is not an alternative in insulin allergy. Diabetes Care, 2003, 26, 2216-2235.
12. Burak-Czapiuk B., Zarzycki W.J.: Analogi insulin ludzkich w zaburzeniach gospodarki wȩglowodanowej - ich zastosowanie kliniczne i działania niepoża̧dane. Przegl. Kardiometabol., 2007, 3, 184-188.
13. Bonenberg A., Siewko K., Popławska-Kita A., Kinalska I.: Insulinoterapia w cukrzycy z uwzglȩdnieniem stosowania analogów. Przegla̧d Kardiometabol., 2007, 3, 189-196.
14. Da̧browski M., Nowakowski A.: Skuteczność, bezpieczeństwo i tolerancja glarginy - długo dział aja̧cego analogu insuliny u dorosłych chorych na cukrzyce typu 1 w codziennej praktyce klinicznej. Diabetol. Prakt., 2007, 8, 119.
15. Pietrzak M.: Intensive functional insulin therapy - analogue acting insulin or regular human insulin. Przew. Lek., 2005, 3, 133-139.